Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2014

01-12-2014 | Pancreatic Tumors

Readmission After Pancreatic Resection: Causes and Causality Pattern

Authors: Eran Sadot, MD, Murray F. Brennan, MD, Ser Yee Lee, MD, Peter J. Allen, MD, Mithat Gönen, PhD, Jeffery S. Groeger, MD, T. Peter Kingham, MD, Michael I. D’Angelica, MD, Ronald P. DeMatteo, MD, William R. Jarnagin, MD, Yuman Fong, MD

Published in: Annals of Surgical Oncology | Issue 13/2014

Login to get access

Abstract

Background

Readmission rates have been targeted for cost/reimbursement control. Our goal was to identify causes for readmission and delineate the pattern of early and late readmission.

Methods

Between 2011 and 2012, a total of 490 patients underwent pancreaticoduodenectomy, distal pancreatectomy or central pancreatectomy. Logistic regression was used to identify predictors of readmission. K-medoids clustering was performed to identify the major readmission subgroups.

Results

Median postoperative length of stay (LOS) was 7 days, and the 30- and 90-day readmission rates were 23 and 29 %, respectively. The most common cause for 30-day readmissions was procedure-related infections (58 %), while the most common cause for 31–90-day readmissions was failure to thrive and chemotherapy-related symptoms (38 %). Independent predictors of 30-day readmissions were central pancreatectomy, discharge with a drain, pancreatic duct <3 mm, previous abdominal surgery, and postoperative LOS. Independent predictors for 31–90-day readmissions were age and preoperative serum carcinoembryonic antigen. Cancer-related covariates were more common in the 31–90-day readmission group. Postoperative carbohydrate antigen 19-9 levels were twofold higher in the 31–90-day readmission group compared with the no readmission group (p = 0.03). K-medoids clustering identified a subgroup where 74 % of readmissions occur at a median of 7 days after discharge.

Conclusions

Readmissions after pancreatic operations are procedure-related in the first 30 days, but those after this period are influenced by the natural history of the underlying diagnosis. The readmission penalty policy should account for the timing of readmission and the natural history of the underlying disease and procedure. Early follow-up for patients at high risk for readmission may minimize early readmissions.
Literature
4.
go back to reference Reddy DM, Townsend CM Jr, Kuo YF, et al. Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg. 2009;13(11):1963–74; discussion 74–5.PubMedCentralPubMedCrossRef Reddy DM, Townsend CM Jr, Kuo YF, et al. Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg. 2009;13(11):1963–74; discussion 74–5.PubMedCentralPubMedCrossRef
5.
go back to reference Yermilov I, Bentrem D, Sekeris E, et al. Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol. 2009;16(3):554–61.PubMedCrossRef Yermilov I, Bentrem D, Sekeris E, et al. Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol. 2009;16(3):554–61.PubMedCrossRef
6.
go back to reference Gawlas I, Sethi M, Winner M, et al. Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol. 2013;20(6):1781–7.PubMedCrossRef Gawlas I, Sethi M, Winner M, et al. Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol. 2013;20(6):1781–7.PubMedCrossRef
7.
go back to reference Schneider EB, Hyder O, Wolfgang CL, et al. Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg. 2012;215(5):607–15.PubMedCentralPubMedCrossRef Schneider EB, Hyder O, Wolfgang CL, et al. Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg. 2012;215(5):607–15.PubMedCentralPubMedCrossRef
8.
go back to reference Zhu ZY, He JK, Wang YF, et al. Multivariable analysis of factors associated with hospital readmission following pancreaticoduodenectomy for malignant diseases. Chin Med J (Engl). 2011;124(7):1022–5.PubMed Zhu ZY, He JK, Wang YF, et al. Multivariable analysis of factors associated with hospital readmission following pancreaticoduodenectomy for malignant diseases. Chin Med J (Engl). 2011;124(7):1022–5.PubMed
9.
go back to reference Fong ZV, Ferrone CR, Thayer SP, et al. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them? A 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014;18(1):144–5.CrossRef Fong ZV, Ferrone CR, Thayer SP, et al. Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them? A 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. J Gastrointest Surg. 2014;18(1):144–5.CrossRef
10.
11.
go back to reference Hyder O, Dodson RM, Nathan H, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg. 2013;148(12):1095–102.PubMedCrossRef Hyder O, Dodson RM, Nathan H, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg. 2013;148(12):1095–102.PubMedCrossRef
12.
go back to reference Park J, Pillarisetty VG, Brennan MF, et al. Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg. 2010;211(3):308–15.PubMedCrossRef Park J, Pillarisetty VG, Brennan MF, et al. Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg. 2010;211(3):308–15.PubMedCrossRef
13.
go back to reference Correa-Gallego C, Brennan MF, D’Angelica M, et al. Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg. 2013;258(6):1051–8.PubMedCrossRef Correa-Gallego C, Brennan MF, D’Angelica M, et al. Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg. 2013;258(6):1051–8.PubMedCrossRef
14.
go back to reference Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg. 2008;207(4):490–8.PubMedCrossRef Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg. 2008;207(4):490–8.PubMedCrossRef
15.
go back to reference Kent TS, Sachs TE, Callery MP, Vollmer CM Jr. Readmission after major pancreatic resection: a necessary evil? J Am Coll Surg. 2011;213(4):515–23.PubMedCrossRef Kent TS, Sachs TE, Callery MP, Vollmer CM Jr. Readmission after major pancreatic resection: a necessary evil? J Am Coll Surg. 2011;213(4):515–23.PubMedCrossRef
16.
go back to reference Ahmad SA, Edwards MJ, Sutton JM, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256(3):529–37.PubMedCrossRef Ahmad SA, Edwards MJ, Sutton JM, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256(3):529–37.PubMedCrossRef
17.
go back to reference Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg. 2006;10(9):1243–52; discussion 52–3.PubMedCrossRef Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg. 2006;10(9):1243–52; discussion 52–3.PubMedCrossRef
18.
go back to reference Leichtle SW, Kaoutzanis C, Mouawad NJ, et al. Classic Whipple versus pylorus-preserving pancreaticoduodenectomy in the ACS NSQIP. J Surg Res. 2013;183(1):170–6.PubMedCrossRef Leichtle SW, Kaoutzanis C, Mouawad NJ, et al. Classic Whipple versus pylorus-preserving pancreaticoduodenectomy in the ACS NSQIP. J Surg Res. 2013;183(1):170–6.PubMedCrossRef
20.
go back to reference Distler M, Pilarsky E, Kersting S, Grutzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas: a retrospective tumor marker prognostic study. Int J Surg. 2013;11(10):1067–72.PubMedCrossRef Distler M, Pilarsky E, Kersting S, Grutzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas: a retrospective tumor marker prognostic study. Int J Surg. 2013;11(10):1067–72.PubMedCrossRef
21.
go back to reference Kanda M, Fujii T, Takami H, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. (Epub 9 Oct 2013). Kanda M, Fujii T, Takami H, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. (Epub 9 Oct 2013).
22.
go back to reference Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681–9.PubMedCrossRef Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681–9.PubMedCrossRef
23.
go back to reference Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530–8.PubMedCrossRef Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530–8.PubMedCrossRef
25.
go back to reference O’Reilly EM, Lowery MA. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J. 2012;18(6):609–13.PubMedCrossRef O’Reilly EM, Lowery MA. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J. 2012;18(6):609–13.PubMedCrossRef
Metadata
Title
Readmission After Pancreatic Resection: Causes and Causality Pattern
Authors
Eran Sadot, MD
Murray F. Brennan, MD
Ser Yee Lee, MD
Peter J. Allen, MD
Mithat Gönen, PhD
Jeffery S. Groeger, MD
T. Peter Kingham, MD
Michael I. D’Angelica, MD
Ronald P. DeMatteo, MD
William R. Jarnagin, MD
Yuman Fong, MD
Publication date
01-12-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 13/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3841-0

Other articles of this Issue 13/2014

Annals of Surgical Oncology 13/2014 Go to the issue